(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.39%.
Xeris Biopharma Holdings's revenue in 2025 is $222,551,000.On average, 2 Wall Street analysts forecast XERS's revenue for 2025 to be $43,393,997,250, with the lowest XERS revenue forecast at $43,273,881,000, and the highest XERS revenue forecast at $43,514,113,500. On average, 3 Wall Street analysts forecast XERS's revenue for 2026 to be $51,874,204,500, with the lowest XERS revenue forecast at $50,416,794,000, and the highest XERS revenue forecast at $54,548,793,000.
In 2027, XERS is forecast to generate $59,417,505,000 in revenue, with the lowest revenue forecast at $55,974,172,500 and the highest revenue forecast at $66,288,154,500.